Ongoing pregnancy · Subfertile women undergoing assisted reproduction
It is very uncertain whether G‐CSF changes ongoing pregnancy rate per woman randomised compared with no treatment or placebo (very low certainty).
1 finding from 1 review
Miscarriage · Subfertile women undergoing assisted reproduction
It is very uncertain whether G‐CSF changes miscarriage rate per woman randomised compared with no treatment or placebo (very low certainty).
1 finding from 1 review
Clinical pregnancy rate · Subfertile women undergoing assisted reproduction
It is very uncertain whether G‐CSF changes clinical pregnancy rate per woman randomised compared with no treatment or placebo (very low certainty).
1 finding from 1 review
Clinical pregnancy rate ‐ unselected or unstated IVF number · Subfertile women undergoing assisted reproduction
G‐CSF showed no clear difference in clinical pregnancy rate ‐ unselected or unstated IVF number compared with no treatment or placebo (low certainty).
1 finding from 1 review
Clinical pregnancy rate ‐ 2 or more IVF failures · Subfertile women undergoing assisted reproduction
G‐CSF may leads to higher clinical pregnancy rate ‐ 2 or more IVF failures compared with no treatment or placebo (low certainty).
1 finding from 1 review
Clinical pregnancy rate ‐ women with thin endometrium · Subfertile women undergoing assisted reproduction
G‐CSF showed no clear difference in clinical pregnancy rate ‐ women with thin endometrium compared with no treatment or placebo (low certainty).
1 finding from 1 review
Multiple pregnancy rate · Subfertile women undergoing assisted reproduction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events per woman · Subfertile women undergoing assisted reproduction
1 finding from 1 review
Overall survival · newly diagnosed patients with myelodysplastic syndromes
It is very uncertain whether G‐CSF changes overall survival compared with placebo (very low certainty).
1 finding from 1 review
Progression‐free survival · newly diagnosed patients with myelodysplastic syndromes
1 finding from 1 review
Time to progression to AML · newly diagnosed patients with myelodysplastic syndromes
1 finding from 1 review
Quality of life · newly diagnosed patients with myelodysplastic syndromes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infections · newly diagnosed patients with myelodysplastic syndromes
1 finding from 1 review
Severe adverse events · newly diagnosed patients with myelodysplastic syndromes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · newly diagnosed patients with myelodysplastic syndromes
1 finding from 1 review
improvement of infection clinical and microbiological assessment · patients with diabetic foot infection
G‐CSF + standard treatment may leads to higher improvement of infection clinical and microbiological assessment compared with usual treatment (low certainty).
1 finding from 1 review
Surgical intervention · patients with diabetic foot infection
G‐CSF + standard treatment may leads to lower need for surgery: Overall Surgical Interventions compared with usual treatment (low certainty).
1 finding from 1 review
Need for surgery: Amputation · patients with diabetic foot infection
G‐CSF + standard treatment may leads to lower need for surgery: Amputation compared with usual treatment (low certainty).
1 finding from 1 review
Granulocyte‐colony stimulating factor (G‐CSF) versus placebo · people undergoing liver transplantation
It is very uncertain whether intervention changes granulocyte‐colony stimulating factor (G‐CSF) versus placebo compared with control (very low certainty).
2 findings from 1 review